

Efficacy and Safety of Low Dose Rivaroxaban in Patients with Coronary Heart Disease: Systematic Review and Meta-Analysis

Safi U. Khan, MD; Muhammad Zia Khan, MD; Zain Ul Abideen Asad, MD; Shahul Valavoor, MD; Muhammad Usman Khan, MD; Muhammad Shahzeb Khan, MD; Troy Krupica, MD; Mohamad Alkhouli, MD; Edo Kaluski, MD

SUPPLEMENTAL MATERIAL

Table S1. PubMed search strategy

("rivaroxaban"[MeSH Terms] OR "rivaroxaban"[All Fields]) AND (("mortality"[Subheading] OR "mortality"[All Fields] OR "mortality"[MeSH Terms]) OR ("cardiovascular diseases"[MeSH Terms] OR ("cardiovascular"[All Fields] AND "diseases"[All Fields]) OR "cardiovascular diseases"[All Fields] OR ("cardiovascular"[All Fields] AND "disease"[All Fields]) OR "cardiovascular disease"[All Fields]) OR ("myocardial infarction"[MeSH Terms] OR ("myocardial"[All Fields] AND "infarction"[All Fields]) OR "myocardial infarction"[All Fields]) AND ("hemorrhage"[MeSH Terms] OR "hemorrhage"[All Fields] OR "bleeding"[All Fields]) OR ("stroke"[MeSH Terms] OR "stroke"[All Fields])) AND (Clinical Trial[ptyp] AND "humans"[MeSH Terms])	231
---	-----

Table S2. Risk of bias in the included trials as assessed by the Cochrane risk of bias assessment scale

Studies	Randomization	Allocation concealment	Blinding (Physician/Patient)	Adjudication of outcomes	Selective outcome reporting	Incomplete data reporting addressed ?	Free of other bias ?
ATLAS ACS-TIMI 46	Green	Green	Green	Green	Yellow	Green	Yellow
ATLAS ACS 2 TIMI 51	Green	Green	Green	Green	Green	Yellow	Yellow
COMPASS	Green	Green	Green	Green	Green	Green	Yellow
GEMINI ACS-1	Green	Green	Green	Green	Green	Green	Yellow
COMMANDER HF	Green	Green	Green	Red	Yellow	Green	Yellow

Green (low risk); yellow (unclear risk); Red (high risk)